Potential Inhalation Therapy for IPF is in Development

  • Research and Development

    Potential Inhalation Therapy for IPF is in Development

    Posted by Pulmonary Fibrosis News Moderator on October 1, 2018 at 6:24 pm

    Samumed and United Therapeutics announced an exclusive license agreement for North American rights to Samumed’s investigational therapy SM04646 to treat idiopathic pulmonary fibrosis (IPF). SM04646 is a small molecule inhibitor of the Wnt signaling pathway, which was previously found to be involved in IPF development. The molecule is believed to reduce the activity of genes associated with fibrosis. It is administered as an inhaled aerosol.

    Click here to learn more about SM04646 and this partnership.

    Are any of your medications administered as an inhaled aerosol? Do you like this method of delivery?

    replied 6 years, 3 months ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .